Wegovy vs. Trulicity

See how Wegovy and Trulicity compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Wegovy and Trulicity are both once-weekly GLP-1 receptor agonist injections, but Wegovy is approved for weight management while Trulicity is approved for type 2 diabetes.

  • Wegovy reduces cardiovascular risk in adults with obesity or overweight and heart disease, while Trulicity does so specifically in adults with type 2 diabetes.

  • Both drugs carry a boxed warning for thyroid tumors and cause similar gastrointestinal side effects like nausea and diarrhea.

Wegovy vs. Trulicity Drug Summary

Wegovy

Wegovy is a GLP-1 receptor agonist (semaglutide) approved for chronic weight management in adults and adolescents with obesity or overweight, and to reduce cardiovascular risk in adults with established heart disease. It's injected once a week, starting at a low dose and increasing every four weeks up to a 2.4 mg maintenance dose.

Trulicity

Trulicity is a GLP-1 receptor agonist (dulaglutide) approved to control blood sugar in adults and children 10 and older with type 2 diabetes, and to lower cardiovascular risk in adults with type 2 diabetes and heart disease or risk factors. It's given as a once-weekly injection with a prefilled pen, starting at 0.75 mg and increasing as needed up to 4.5 mg.

Wegovy vs. Trulicity Side Effects

Wegovy

Most common
nausea (up to 44%)
diarrhea (up to 30%)
vomiting (up to 24%)
abdominal pain (up to 20%)

Trulicity

Most common
nausea (up to 21.1%)
diarrhea (up to 13%)
vomiting (up to 13%)
abdominal pain (up to 13%)

Wegovy vs. Trulicity Dosage

Wegovy

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2.4 mg once weekly Week 17 onward
Dose changes 4 increases Every 4 weeks

Trulicity

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.75 mg once weekly Weeks 1-4
Maximum dose 4.5 mg once weekly If needed
Dose changes 3 increases Every 4 weeks

Wegovy vs. Trulicity Indications

Wegovy

Wegovy is FDA-approved for chronic weight management alongside diet and exercise in adults and teens 12 and older with obesity or overweight plus a weight-related condition. It's also approved to reduce the risk of major cardiovascular events in adults with obesity or overweight and existing heart disease.

  • Chronic weight management in adults with obesity or overweight

  • Approved for adolescents 12 and older

  • Reduces risk of heart attack, stroke, and cardiovascular death

  • Requires a weight-related condition or established heart disease

  • Not approved for diabetes blood sugar control

Trulicity

Trulicity is FDA-approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes, alongside diet and exercise. It's also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes who have heart disease or multiple risk factors.

  • Blood sugar control in adults with type 2 diabetes

  • Approved for children 10 and older with type 2 diabetes

  • Reduces cardiovascular risk in adults with type 2 diabetes

  • Sometimes used off-label for weight loss without diabetes

  • Not approved as a primary weight-loss treatment

Wegovy vs. Trulicity Pros and Cons

Wegovy

Wegovy uses a higher maintenance dose than diabetes-focused semaglutide products, which may translate to greater weight loss. It carries the same boxed warning for thyroid tumors as other GLP-1 drugs and shares similar gastrointestinal side effects with Trulicity.

Pros

  • FDA-approved specifically for weight management, not just off-label use

  • Approved to reduce cardiovascular risk in people without diabetes

  • Approved for adolescents 12 and older

  • Uses a higher maintenance dose (2.4 mg) than diabetes GLP-1 options

Cons

  • Not approved for blood sugar control in type 2 diabetes

  • Newer drug (2021) with less long-term real-world data

  • Higher rates of nausea and diarrhea reported in trials

  • No pediatric type 2 diabetes indication

Trulicity

Trulicity has been on the market since 2014, giving it a longer track record than Wegovy. It's specifically approved for type 2 diabetes and pediatric use, but any weight-loss benefit is considered off-label.

Pros

  • Longer track record with over a decade of real-world use

  • Approved for children as young as 10 with type 2 diabetes

  • Lower reported rates of nausea and diarrhea in trials

  • Available in multiple maintenance doses for gradual adjustment

Cons

  • No FDA-approved weight-loss indication; use for weight loss is off-label

  • Not approved to treat obesity or overweight without diabetes

  • Lower maximum dose may mean less weight loss than Wegovy

  • Cardiovascular benefit only established in people with type 2 diabetes

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.